Evotec (NASDAQ:EVO) Shares Gap Down - What's Next?

Key Points

• Evotec shares opened lower, falling from a prior close of $1.96 to $1.9191 before last trading at $1.92.
• Analyst sentiment has weakened: multiple firms downgraded the stock or cut price targets, resulting in a consensus “Hold” rating and an average target price of $3.00.
• Evotec’s shares remain below their 50-day and 200-day moving averages, while hedge funds and other institutional investors own a relatively small 5.81% stake.

Evotec AG (NASDAQ:EVO - Get Free Report) shares gapped down before the market opened on Friday . The stock had previously closed at $1.96, but opened at $1.9191. Evotec shares last traded at $1.92, with a volume of 4,361 shares.

Analysts Set New Price Targets

Several equities analysts recently issued reports on the company. HC Wainwright dropped their price target on Evotec from $7.00 to $4.00 and set a "buy" rating on the stock in a research report on Wednesday, July 15th. Wall Street Zen downgraded Evotec from a "hold" rating to a "sell" rating in a research note on Saturday, May 9th. Berenberg Bank cut Evotec from a "buy" rating to a "hold" rating in a research note on Thursday, July 16th. Weiss Ratings reaffirmed a "sell (d-)" rating on shares of Evotec in a report on Tuesday, July 21st. Finally, TD Cowen lowered shares of Evotec from a "buy" rating to a "hold" rating and set a $2.00 price objective on the stock. in a research report on Wednesday, July 15th. Two analysts have rated the stock with a Buy rating, two have given a Hold rating and one has given a Sell rating to the company's stock. Based on data from MarketBeat, the company has a consensus rating of "Hold" and an average target price of $3.00.

Evotec Stock Down 0.5%

The stock's fifty day moving average price is $2.32 and its 200-day moving average price is $2.75. The company has a quick ratio of 2.21, a current ratio of 2.33 and a debt-to-equity ratio of 0.62.

Institutional Inflows and Outflows

A number of hedge funds have recently added to or reduced their stakes in EVO. Apollon Wealth Management LLC purchased a new stake in shares of Evotec during the 1st quarter worth approximately $28,000. Marshall Wace LLP acquired a new position in Evotec during the fourth quarter worth $40,000. SmartHarvest Portfolios LLC acquired a new position in Evotec during the first quarter worth $44,000. BNP Paribas Financial Markets boosted its position in Evotec by 62.2% during the second quarter. BNP Paribas Financial Markets now owns 12,000 shares of the company's stock worth $50,000 after purchasing an additional 4,600 shares in the last quarter. Finally, Bank of America Corp DE grew its holdings in Evotec by 262.5% in the fourth quarter. Bank of America Corp DE now owns 12,828 shares of the company's stock valued at $53,000 after purchasing an additional 9,289 shares during the last quarter. 5.81% of the stock is owned by hedge funds and other institutional investors.

About Evotec

Evotec SE NASDAQ: EVO is a global biotechnology company headquartered in Hamburg, Germany, specializing in drug discovery and development partnerships. The company leverages its integrated discovery platforms to support pharmaceutical and biotech clients in advancing novel therapies from target identification through preclinical development.

Evotec's service offering encompasses high-throughput screening, bioanalytics, combinatorial chemistry, structural biology, pharmacology, and computational drug design.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source